Interleukin-1 receptor type I - Amgen

Drug Profile

Interleukin-1 receptor type I - Amgen

Alternative Names: IL-1RI - Amgen; Interleukin-1 receptor type 1 - Amgen; Soluble IL-1 receptor type I - Amgen

Latest Information Update: 06 Jun 2002

Price : $50

At a glance

  • Originator Amgen
  • Class
  • Mechanism of Action Immunosuppressants; Interleukin 1 beta inhibitors; Interleukin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Graft-versus-host disease; HIV-1 infections; Hypersensitivity; Myeloid leukaemia; Transplant rejection; Type 1 diabetes mellitus
  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 06 Jun 2002 No development reported - Phase-I/II for HIV-1 infections in USA (SC)
  • 06 Jun 2002 No development reported - Phase-I for Myeloid leukaemia in USA (Injection)
  • 06 Jun 2002 No development reported - Phase-I for Transplant rejection in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top